Ivuxolimab

Summary

Ivuxolimab (CHEMBL4297883) is a phase-3 clinical-stage antibody; indicated across 8 conditions including clear cell renal carcinoma and triple-negative breast carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 8 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297883
Name	Ivuxolimab
Type	Antibody
Max phase	3

Also known as: Anti-ox40 antibody pf-04518600, Ivuxolimab, Pf-04518600, PF-04518600, PF-8600, Pf04518600, PF04518600, IVUXOLIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
triple-negative breast carcinoma	2	MONDO:0005494	EFO:0005537
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
metastatic prostate carcinoma	1	MONDO:0004956	EFO:0000196
neoplasm	1	MONDO:0005070	EFO:0000616
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
follicular lymphoma	1	MONDO:0018906	MONDO:0018906

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05059522	PHASE3	ACTIVE_NOT_RECRUITING	Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT03092856	PHASE2	ACTIVE_NOT_RECRUITING	Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03217747	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
NCT03971409	PHASE2	ACTIVE_NOT_RECRUITING	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT02554812	PHASE1/PHASE2	TERMINATED	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT02315066	PHASE1	COMPLETED	Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
NCT03636503	PHASE1	TERMINATED	Rituximab + Immunotherapy in Follicular Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).